34
Participants
Start Date
October 31, 2005
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Docetaxel
Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
Carboplatin
Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
Docetaxel
Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
Liposomal doxorubicin
Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
University Hospital of Crete, Heraklion
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli
"IASO General Hospital of Athnes, Dep of Medical Oncology", Athens
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens
"Department of Medical Oncology, Marika Iliadis Hospital of Athens", Athens
Department of Medical Oncology, Air Forces Military Hospital of Athens, Athens
Medical Oncology Unit, 401 Military Hospital of Athens, Athens
State General Hospital of Larissa, Dep of Medical Oncology, Larissa
"First Department of Medical Oncology, Metaxa's Anticancer Hospital of Pireas", Piraeus
"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki
Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki, Thessaloniki
"Medical Oncology Unit, AXEPA General Hospital of Thessaloniki", Thessaloniki
Lead Sponsor
University Hospital of Crete
OTHER
Hellenic Oncology Research Group
OTHER